Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world.
The study objectives are to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic outcomes in patients with treated acute VTE (DVT and PE) in the real-world setting.
Global, prospective, observational, multi-centre VTE registry to be conducted in sequential cohorts.
In order to observe temporal trends in management of VTE a minimum of 2 cohorts will be recruited. Recruitment into the second (or subsequent cohorts) will commence when recruitment is completed into the first or previous cohort. It is estimated that each cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis.
5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months
A further 5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.